Jump to main content

Knopp Biosciences

Knopp Biosciences

Leading the Way

Knopp is led by an experienced executive team, notable for its depth and breadth of expertise in drug discovery, development, and commercialization. With decades of experience in the pharma industry, members of the Knopp team have been responsible for numerous biological discoveries, pivotal clinical studies, and new drug approvals, especially in neurology.

Leadership Team

  • Michael E. Bozik, M.D.

    Michael E. Bozik, M.D.

    President and Chief Executive Officer

    Prior to joining Knopp, Dr. Bozik served as vice president of global research and development for Bayer Healthcare LLC, Consumer Care Division. Previously he served Bristol-Myers Squibb Company as vice president of neuroscience clinical development and as vice president of research, development, and business operations in the consumer medicines and specialty pharmaceuticals group. Earlier in his career he directed the Brain Tumor Center at the University of Pittsburgh Cancer Institute and served as chief of the Division of Neuro-Oncology in the University’s Department of Neurosurgery. Dr. Bozik received his B.A. from the University of Notre Dame, his M.D. from the University of Pittsburgh, and conducted his residency and fellowship training in neurology and neuro-oncology at the University of Michigan and the University of Pittsburgh. He is a director of the Pennsylvania Biotechnology Association and a recipient of the Ernst & Young Entrepreneur of the Year Award.

  • Mark Kreston

    Mark Kreston

    Chief Commercial Officer

    Mark brings 30 years of drug commercialization experience to Knopp, most recently at Celgene, where he served as Corporate VP of Global Marketing, Inflammation & Immunology. Previously he served at Johnson & Johnson as Worldwide VP Global Marketing, Immunology. Earlier, at Bristol-Myers Squibb, he was Worldwide VP Global Marketing, Immunology, and served as President of Consumer Medicines. His record of major pharmaceutical product launches includes Otezla for psoriasis and Orencia for rheumatoid arthritis. Early in his career he was product manager for Tylenol and Pepcid at McNeil Consumer Healthcare. Mark is a graduate of the University of Pennsylvania and the Cornell Johnson Graduate School of Management.

  • Gregory T. Hebrank, M.D., MBA

    Gregory T. Hebrank, M.D., MBA

    EVP, Corporate Operations & Finance

    Dr. Hebrank, a co-founder of Knopp, is a successful longtime investor in public and private biotech equities and was the co-founder of and a partner in a successful clinical obstetrics and gynecologic practice in Westmoreland County, Pennsylvania. Dr. Hebrank earned a B.S. in Biomedical Engineering from Vanderbilt University, an M.D. from Tulane University School of Medicine, and completed his residency training in obstetrics and gynecology at Magee-Women’s Hospital, a part of the University of Pittsburgh Medical Center. He completed his M.B.A. at Carnegie Mellon University’s Tepper School of Business. He serves on the board of LaunchCyte LLC.

  • Thomas Petzinger Jr.

    Thomas Petzinger Jr.

    Business Development & Public Affairs

    Mr. Petzinger is a founder of LaunchCyte LLC, a life sciences incubator that co-founded Knopp. He also serves as a director of other LaunchCyte companies, including Immunetrics Inc., Crystalplex Corp., Reaction Biology Corp., and Celsense Inc. He is also a director of Lipella Pharmaceuticals Inc. and WESA 90.5 FM, Pittsburgh. Prior to co-founding LaunchCyte, he spent 22 years at The Wall Street Journal, where he served as Washington economics editor, deputy Washington bureau chief, millennium editor, and weekly columnist. He has also written three business books, two selected as notable books of the year by The New York Times. He received his B.S. in Journalism from Northwestern University, where he was a Richter International Scholar.

  • Steven Dworetzky, Ph.D.

    Steven Dworetzky, Ph.D.

    Chief Scientific Officer

    Dr. Dworetzky brings a lengthy record of pharmaceutical discovery to Knopp. Previous to joining Knopp in 2007, he was a senior principal research investigator for the neuroscience group at Bristol-Myers Squibb, responsible for leading programs in neuroprotection, schizophrenia, and pain discovery, with an emphasis on ion channel modulation. During his tenure, Dr. Dworetzky’s research yielded seven issued U.S. patents for which he is an inventor. He is the author of over 40 peer-reviewed publications. He holds a B.A. in biology and chemistry from Skidmore College and a Ph.D. in cell biology from the University of Florida and was an adjunct assistant professor of molecular physiology at Yale University.

  • Donald G. Archibald

    Donald G. Archibald

    Senior Director, Biostatistics

    Mr. Archibald's biostatistics strategy, consulting, and department leadership work in clinical drug development spans 40 years. He was the lead statistician for several successful FDA and International approvals of drugs for the treatment of arrhythmia, depression, schizophrenia, and bipolar disorder. He is co-author on over 20 publications including a New England Journal of Medicine publication of one of the first pivotal studies to demonstrate the role of aspirin in preventing cardiovascular events. He has extensive experience interacting with federal regulatory agencies in areas including: end of Phase I, end of Phase II, Special Protocol Assessment, Pre-NDA filing, advisory committee presentations, and labeling and safety issues. Prior to joining Knopp, he was the Director Biostatistics at Bristol Myers Squibb and a Senior Biostatistician for the Cooperative Studies Program at the VA Medical Center. Mr. Archibald completed his M.Phil., Statistics at Yale University, his M.S., Mathematics at Rensselaer Polytechnic Institute, and received his B.S., Mathematics at Fairfield University.

  • Calman Prussin, M.D.

    Calman Prussin, M.D.

    Vice President of Clinical and Translational Research

    Dr. Prussin comes to Knopp from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health (NIH). He has acted as principal investigator in numerous clinical trials in eosinophil-associated diseases, served on the Pulmonary-Allergy Drugs Advisory Committee of the Food and Drug Administration, and is the author of 100 peer-reviewed research papers, review articles, book chapters, and abstracts. He is a past chair of the American Board of Allergy and Immunology.

    A Fellow of the American Academy of Allergy and Immunology, Dr. Prussin received his B.A. in chemistry at the University of California, San Diego, and his M.D. from the USC Keck School of Medicine; conducted his training in internal medicine at Los Angeles County-USC Medical Center; and completed both basic science and clinical allergy & immunology fellowship training at NIAID. He has been the recipient of numerous awards and service medals from the U.S. Public Health Service, from which he retired with the rank of Captain.

  • Jim Mather

    Jim Mather

    Vice President, Clinical Operations and Data Management

    Jim Mather has 30 years’ experience in clinical research and development as a Phase 1 clinical operations manager, director of study operations for Phase 2-4 clinical trials, supervisor of data management and biostatistics, and vendor management.  He developed and conducted studies for both small and mid-sized biotech pharma, as well for a top five large pharma company during his time as a CRO clinical operations group lead.

Board of Directors

  • Benjamin A. Gomez

    Managing Director of Pilot House Associates, LLC

    Mr. Gomez serves as Managing Director of Pilot House Associates, a family investment office in Boston. He joined Pilot House in 1998 as Treasurer. Prior to joining Pilot House, Mr. Gomez held various positions at Continental Cablevision and the Bank of New York. He received a bachelor's degree in Foreign Service, with honors, from Georgetown University and an MBA from Columbia University's Graduate School of Business.

  • Jeffrey S. McCormick

    Chairman and Managing General Partner of Saturn Capital

    Mr. McCormick is the Chairman and Managing General Partner of Saturn. He founded Saturn in 1993, focusing on energy, electronic commerce, specialty materials, and select opportunistic investments. He then led the expansion of Saturn with the launch of both Saturn Partners Limited Partnership I and II. Mr. McCormick has over 20 years of experience as an investment banker, entrepreneur and venture capitalist. He currently serves on the boards of MooBella, American Made, SureLogic, Applied Clean Tech, and NHXS. Mr. McCormick is a graduate of Syracuse University, where he received an MBA in Finance and a B.S. in biology.

  • Michael E. Bozik, M.D.

  • Gregory T. Hebrank, M.D., MBA

  • Thomas Petzinger Jr.